| Project/Area Number |
22591555
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
II Masaki 大阪医科大学, 医学部, 講師 (10442922)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 心臓大血管外科学 / 細胞治療 / 遺伝子治療 / 血管新生 |
|---|
| Research Abstract |
The activation of SHh signaling by SHh treatment of human CD34+cells enhanced the migration, proliferation, adhesion, and colony forming capacities thatare essential for neovascularization including vasculogenesis/arteriogenesis. We havedemonstrated the differentiation potential of CD34+ cells into both endothelial cells andvascular smooth muscle cells exhibiting up-regulation of genes expressed in vascularlineage cells. The SHh activated human CD34+ cells directly contributed to vascularregeneration while non-activated CD34+ cells showed less regenerative capacity in a mouseischemic hindlimb model. The activation of cellular SHh signaling may increase thepotency of autologous CD34+ cell therapy in ischemic diseases.
|
